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ORIGINAL ARTICLETrim32 Deficiency Enhances Th2 Immunity
and Predisposes to Features of Atopic
Dermatitis
Yuangang Liu1, Zhiping Wang1, Rachel De La Torre1, Ashley Barling1, Takahiro Tsujikawa2,
Noah Hornick1, Jon Hanifin1, Eric Simpson1, Yun Wang1, Emily Swanzey1, Aaron Wortham1,
Hao Ding3, Lisa M. Coussens2 and Molly Kulesz-Martin1,2Altered innate immunity is a feature of certain skin inflammatory diseases such as psoriasis and atopic
dermatitis (AD). In this study, we provide evidence that deficiency in Trim32 (a tripartite motif [TRIM] protein
with innate antiviral activity) contributes to a T helper type 2 biased response and predisposes to features of AD
in mice. On treatment with the toll-like receptor 7 agonist imquimod (IMQ), Trim32 knockout mice displayed
compromised psoriasiform phenotypes and defective T helper type 17 response. Instead, IMQ treatment of
Trim32 knockout mice induced AD-like phenotypes with enhanced skin infiltration of eosinophils and mast
cells, elevation of T helper type 2 cytokines/chemokines expression, and reduced expression of filaggrin
protein expression. Furthermore, although the induction of phosphorylated Stat3 and RelA was compromised
after IMQ treatment in the knockout mice, phosphorylated Stat6 was elevated. CC chemokine ligand 20
induction by tumor necrosis factor-a and IL-17A was reduced in Trim32-deficient keratinocytes, whereas CC
chemokine ligand 5 induction by tumor necrosis factor-a and IL-4 was enhanced. In addition, Trim32 protein
levels were elevated in mice treated with IMQ. Unlike Trim32 overexpression in psoriasis, TRIM32 levels were
low in patients with AD. Based on Trim32 induction by IMQ, the lower levels of TRIM32 in AD skin compared
with healthy control and psoriatic skin suggest a defective TRIM32 pathway in AD pathogenesis.
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Innate immunity is the first line of defense against environ-
mental insults and is crucial for initiation of the adaptive
immune response. Aberrant innate immunity has been
implicated in many skin inflammatory diseases, such as
psoriasis and atopic dermatitis (AD). Enhanced innate im-
mune response is associated with psoriasis, whereas defec-
tive innate immunity contributes to AD pathogenesis, as
indicated by reduced expression of antimicrobial peptides
and susceptibility to bacterial and viral infection (De
Benedetto et al., 2009). Single nucleotide polymorphisms
in genes in the innate immune signaling pathways, such as
toll-like receptor (TLR)1/2/6/9 and NOD1/2, have been
associated with AD (Ahmad-Nejad et al., 2004; Early
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However, the causal relationship between defective innate
immunity and AD pathogenesis in animal models remains to
be defined.
Trim32 is a member of the Trim E3-ubiquitin ligase family.
The Trim proteins in this family are mainly involved in innate
antiviral immunity. They inhibit viral infection through
different mechanisms, such as blocking viral entry, transcrip-
tion, assembly, and release (Rajsbaum et al., 2014). Trim32
was initially identified as an HIV tat-associated protein (Fridell
et al., 1995). Trim32 restricts the replication of influenza A
virus by targeting viral RNA polymerase for degradation (Fu
et al., 2015). Like many other TRIM proteins, it regulates the
signaling pathways triggered by innate immunity pattern
recognition receptors. Trim32 activates STING, which is a
sensor for cytoplasmic DNA essential for innate antiviral
response (Zhang et al., 2012). We previously showed that
Trim32 can activate NF-kB through the degradation of Piasy, a
negative regulator of NF-kB (Albor et al., 2006). TRIM32 gene
and protein mutations are associated with human diseases,
including limb-girdle muscular dystrophy (Shieh et al., 2011)
and Bardet-Biedl syndrome (Chiang et al., 2006), as well as
attention deficit/hyperactivity disorder (Lionel et al., 2011), a
condition that has been associated with AD (Eichenfield et al.,
2014; Schmitt et al., 2013).
In the current study, we discovered that Trim32 knockout
(KO) mice displayed an AD-like inflammatory skin condition
in response to imiquimod (IMQ) treatment, including (1)
elevated IL-4, IL-5, and CC chemokine ligand 5 (CCL5)
and reduced IL-17A, CCL20, and S100A9 expression; (2)estigative Dermatology. This is an open access
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Figure 1. Skin morphologic abnormalities induced by IMQ in WT and KO
mice. (a) Representative pictures of gross appearance of back skin from WT
and KO mice in response to vehicle or IMQ treatment at day 6. (b)
Representative hematoxylin and eosin staining of tissue sections of back skin
treated with vehicle or IMQ at day 6. Scale bar¼ 200 mm. n¼ 3e5 per group.
IMQ, imiquimod; KO, knockout; WT, wild type.
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360increased presence of eosinophils and mast cells; and (3)
reduced expression of filaggrin protein. Compared with
patient-matched nonlesional skin and skin of healthy con-
trols, TRIM32 protein levels were high in psoriasis and low in
AD lesional skin. Taken together, our results suggest that
Trim32 is required for normal T helper type 17 (Th17)
response, whereas Trim32 deficiency favors features of a Th2
atopic response.
RESULTS
IMQ-induced psoriasis-like phenotypes are compromised by
Trim32 deficiency
Based on our previous report that TRIM32 protein is elevated
in the epidermal lesions of human psoriasis and activates
keratinocyte production of CCL20 (Liu et al., 2010), we
investigated whether Trim32 is required for the development
of psoriasis-like phenotypes in mice. Using an established
IMQ-treated mouse psoriasis model (van der Fits et al., 2009),
we evaluated gross, histologic, and molecular endpoints
associated with IMQ-induced psoriasis pathogenesis in
Trim32 KO mice and their control wild-type (WT) littermates.
The gross appearance of the back skin of the WT mice treated
with IMQ displayed more scaling than that of KO mice
(Figure 1a). Consistent with less skin scaling in Trim32 KO
mice, hyperkeratosis and parakeratosis were less pronounced
in Trim32 KO mice (Figure 1b, Supplementary Figure S1
online). Taken together, these results indicate that the
development of psoriasis-like phenotypes is compromised by
Trim32 deficiency.
Reduced Th17 and increased Th2 cytokines by Trim32
deficiency
To determine the molecular features underlying these
phenotypic changes, we evaluated the expression profiles of
cytokines and chemokines in response to IMQ in Trim32WT
versus KO mice. As expected, IL-17A was induced by IMQ
treatment in the WT mice; however, its induction was
significantly reduced in the KO mice under the same con-
ditions (Figure 2a). In keeping with defective Th17 immunity,
the induction of CCL20 and antimicrobial peptide S100A9
was significantly reduced in the Trim32 KO mice (Figure 2bJournal of Investigative Dermatology (2017), Volume 137and c, respectively). Th2 cytokines, IL-5 and IL-4, were
upregulated in skin in response to IMQ in Trim32 KO mice
(Figure 2d and e), corroborated by increased serum IL-4 in
Trim32 KO mice (Supplementary Figure S2a online). Similar
chemokine/cytokine profiling was observed in Trim32 KO
mice in another genetic background (129XC57BL/6J), indi-
cating that the essential findings are reproducible and not
strictly mouse strain dependent (Supplementary Figure S3aef
online). Consistent with Trim32 deficiency conferring defec-
tive Th17 response, overexpressing Trim32 in epidermis
predictably enhanced psoriasis-like phenotypes with
increased expression of IL-23, IL-17f, CCL20, and neutrophil
chemokine CXCL5 (Supplementary Figure S4 online). The
expression of IL-17A and CCL20 is mediated through Stat3
(Hau et al., 2014; Li et al., 2015; Mack et al., 2012), whereas
the expression of IL-4 and IL-5 is mediated through Stat6
(Chan et al., 2001; Nelms et al., 1999). Examination of the
IMQ-treated mouse skin revealed induction of phosphory-
lated Stat3 (Y705) in the WT mice and, conversely, induction
of phosphorylated Stat6 (Y641) in the Trim32 KO mice
(Figure 2g). Collectively, these results indicate that Trim32
contributes to IMQ-mediated Th17 activation and that
Trim32 deficiency impairs Th17 response and favors Th2
activation.
IMQ differentially induces the infiltration of T helper, mast
cells, and eosinophils in Trim32-deficient mice
To test the cell types that contribute to altered cytokine
expression by Trim32 deficiency, the presence of Th2 and
Th17 cells in IMQ-treated skin was evaluated using multiplex
sequential immunohistochemistry. Consistent with reduced
IL-17A expression in Trim32 KO mice (Figure 2a), Th17 cells
(IL23Rþ/CD4þ) were significantly reduced, and the presence
of Th2 cells (Gata3þ/CD4þ) was marginally increased in
Trim32 KO mice (Figure 3aec, Supplementary Figure S5
online). Besides Th2 cells, mast cells and eosinophils are
other major cell types that express IL-4 (Gessner et al., 2005;
McLeod et al., 2015). We found that CCL5, a chemokine for
eosinophils and mast cells (Beck et al., 1997; Juremalm et al.,
2002), was significantly increased in the skin of Trim32 KO
mice (Figure 2f). In keeping with this upregulation, Trim32
KO mice displayed significantly increased infiltration of eo-
sinophils (Figure 3d and e) and mast cells (Figure 3f and g) in
response to IMQ treatment. Furthermore, serum IgE levels
were significantly elevated in the Trim32 KO mice
(Figure S2b). These lines of evidence indicate that Trim32
deficiency contributes to the development of AD-like phe-
notypes in response to IMQ.
Trim32 deficiency compromises filaggrin expression in
response to IMQ
AD is an inflammatory skin disease featured by Th2 polari-
zation, barrier defects, and susceptibility to infection. To
further define the relevance of Trim32 deficiency in AD, we
evaluated the expression of filaggrin, a barrier protein
mutated or downregulated in AD (O’Regan et al., 2008).
Filaggrin protein was barely detectable in the whole skin
tissue lysate but was prominently induced by IMQ
(Supplementary Figure S6 online, Figure 4a). Compared with
WT mice, the levels of total filaggrin protein, filaggrin mul-
timer, and filaggrin fragments were reduced in Trim32 KO
Figure 2. IMQ treatment of Trim32 KO mice enhanced Th2 while repressing
Th17 cytokine profile. (aef) Relative mRNA fold change for vehicle- or IMQ-
treated mice by qRT-PCR. Data were normalized by GAPDH mRNA
expression followed by normalization to the WT vehicle-exposed mice
(*P < 0.05, two-way analysis of variance followed by the Bonferroni post-test,
**P < 0.05, an unpaired Student t test). (g) Western blot analysis of phospho-
STAT3 (Y705) and phospho-Stat6 (Y641) from the skin of Trim32 WT and KO
mice treated with IMQ. GAPDH was used as loading control. CCL, CC
chemokine ligand; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
IMQ, imiquimod; KO, knockout; STAT, signal transducer and activator of
transcription; Th, T helper; WT, wild type.
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deficiency (data not shown), suggesting that Trim32 effects
are posttranscriptional. Further analysis of filaggrin by im-
munostaining revealed that cellular filaggrin expression in
the epidermis was significantly reduced in Trim32 KO mice
(Figure 4b and c).
Trim32 deficiency enhances AD-like phenotypes in an
MC903-induced AD mouse model
The role of Trim32 deficiency in AD pathogenesis was further
evaluated in an AD mouse model induced by MC903 (Li
et al., 2006, 2008). Histologic analysis of the treated skin
revealed that Trim32 KO mice displayed a significantly
thicker epidermis in response to MC903 treatment
(Supplementary Figure S7a and b online). Furthermore,
eosinophil infiltration was significantly elevated in MC903-
treated KO mice compared with their WT control litter-
mates (Supplementary Figure S7c and d). IL-4 was elevated in
Trim32 KO mice and further increased in response to MC903
treatment (Supplementary Figure S7e). Similar to IL-4, thymic
stromal lymphopoietin, another key cytokine essential for
Th2-associated inflammation in AD, was increased in Trim32
KO mice in response to MC903. Thymic stromal lympho-
poietin basal levels were higher in Trim32 KO mice and
further induced by MC903 than in WT mice (Supplementary
Figure S7f). Thus, Trim32 deficiency associated with AD-like
phenotypes was validated in an AD mouse model.
Trim32 deficiency reduces CCL20 and enhances CCL5
expression in keratinocytes
Because changes in the chemokines in whole skin samples
(shown in Figure 2 and Supplementary Figure S3 for the
IMQ-treated mice) are mainly attributed to keratinocytes, we
further characterized cultured keratinocytes from WT and
Trim32 KO mice. Analysis of chemokine expression revealed
that CCL20 expression was reduced in response to tumor
necrosis factor-a (TNF-a) and IL-17A and that CCL5 expres-
sion was enhanced by TNF-a or TNF-a plus IL-4 in Trim32
KO keratinocyte cultures (Figure 5a and b). Further analysis
of the induction pattern revealed that Trim32 primarily
affected the induction by TNF-a but not IL-4 or IL-17A. This
suggests that the converse regulation of CCL20 and CCL5
expression by Trim32 is mediated at least in part through
TNF-a signaling. Consistent with NF-kB activation by Trim32
overexpression in our previous studies (Albor et al., 2006),
NF-kB activation was compromised in the skin of Trim32 KO
mice as indicated by reduced RelA phosphorylation and
reduced expression of NF-kB downstream gene A20
(Figure 5c). Similarly, NF-kB activation by TNF-a and IL-
17A was compromised in Trim32-deficient keratinocytes
(Figure 5d).
Trim32 induction is defective in AD
To determine whether Trim32 deficiency is relevant to human
AD, we compared TRIM32 levels in AD and psoriasis biopsy
samples with healthy controls. TRIM32 levels in the nonle-
sional skin from psoriasis were similar to those in the skin
from control individuals. Compared with nonlesional skin,
the TRIM32 levels were significantly higher in the lesional
psoriatic epidermis; furthermore, the TRIM32 protein levels
were significantly lower in both lesional skin and nonlesionalwww.jidonline.org 361
Figure 3. IMQ treatment results in
lower levels of Th17 cells and
elevated mast cell and eosinophil
infiltration in the Trim32 KO mice. (a)
Representative images of CD4þ,
CD4þ/IL23Rþ, and CD4þ/GATA3þ
cells in the skin of WT and Trim32 KO
mice treated with IMQ for 6 days (n ¼
4). (b) Quantification of the number of
CD4þ/IL23Rþ cells (Th17) averaged
for each animal (**P < 0.05, an
unpaired Student t test). (c)
Quantification of the number of
CD4þ/GATA3þ cells (Th2) averaged
for each animal. (d) Representative
images of eosinophil staining of
vehicle- or IMQ-treated mice (n  4).
(e) Quantification of the number of
eosinophils averaged for each animal
(**P < 0.05, an unpaired Student t
test). (f) Representative images of the
mast cell staining of vehicle- or
IMQ-treated mice (n  4). (g)
Quantification of the number of mast
cells averaged for each animal (*P <
0.05, two-way analysis of variance
followed by the Bonferroni post-test).
Scale bar ¼ 100 mm (a) and 200 mm (d
and f). IMQ, imiquimod; KO,
knockout; Th, T helper; WT, wild type.
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362skin from patients with AD compared with that from psoriatic
epidermis and healthy skin (Figure 6a and b). This is consis-
tent with reduced TRIM32 mRNA expression reported in
patients with AD (Guttman-Yassky et al., 2009). As an innate
antiviral protein, the expression of many TRIM proteins can
be induced by viral infection and CpG stimulation (Rajsbaum
et al., 2008). Analysis of Trim32 expression in the IMQ model
revealed that Trim32 was induced by IMQ at the protein level
(Figure 6c). Considering that AD skin is under constant
challenge from pathogens (Hauser et al., 1985; Park et al.,
2013), the low levels of TRIM32 in AD lesional skin sug-
gest defective TRIM32 induction in AD.Journal of Investigative Dermatology (2017), Volume 137DISCUSSION
In this study, we provide evidence to support the contribution
of defective innate immunity in AD pathogenesis with Trim32
knockout mice as a model. Trim32 belongs to a family of
proteins with members involved in innate immunity (Kawai
and Akira, 2010; Versteeg et al., 2014). Specifically,
TRIM32 contributes to innate immunity by (1) restricting viral
replication (Fu et al., 2015; Uchil et al., 2008), (2) inhibiting
viral protein activity (Fatima et al., 2016; Fridell et al., 1995),
and (3) activating innate immune signaling pathways (Albor
et al., 2006; Uchil et al., 2013; Zhang et al., 2012). Consis-
tent with our previous report that TRIM32 protein is elevated
Figure 4. Filaggrin is downregulated in Trim32 KO mice in response to IMQ
treatment. (a) Western blot analysis of filaggrin expression from the skin of
Trim32 WT and KO mice treated with IMQ for 6 days. Keratin 5 was
used as loading control (n ¼ 4). (b) Representative images of indirect
immunofluorescence of filaggrin antibody reactivity in IMQ-treated mice and
zoomed in images (lower panels). Scale bar ¼ 50 mm. (c) Quantification of
integrated fluorescent density of epidermal filaggrin staining (FIJI ImageJ
Software, P ¼ 0.055). IMQ, imiquimod; KO, knockout; WT, wild type.
Figure 5. Altered chemokine expression from neonatal keratinocytes
derived from WT and KO mice and compromised NF-kB activation in
Trim32 KO keratinocytes. (a, b) mRNAs were isolated from primary neonatal
keratinocytes after cytokine treatment as indicated. Expression levels were
determined by qPCR and normalized by GAPDH (*P < 0.05, two-way
analysis of variance followed by the Bonferroni post-test). Data are
representative of three independent experiments. (c) Western blot analysis of
phosphorylation of RelA and its downstream targets A20 expression from the
skin of Trim32WTand KO mice treated with IMQ for 6 days. (d) Western blot
analysis of RelA phosphorylation and A20 expression in response to TNF-a/
IL-17 (T/IL) in cultured keratinocytes. GAPDH was used as loading control.
CCL, CC chemokine ligand; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; IMQ, imiquimod; KO, knockout; TNF-a, tumor necrosis
factor-a; WT, wild type.
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can activate keratinocyte production of CCL20 (Liu et al.,
2010), we verified that Trim32 KO mice were deficient in
mounting features of a Th17 response to TLR activation in the
IMQ model of psoriasis-like disease in mice. Interestingly,
Trim32 KO mice developed AD-like phenotypes character-
ized with dermal infiltration of eosinophils and mast cells,
overexpression of Th2 cytokines, and enhanced Stat6 phos-
phorylation. In conjunction with reduced Trim32 expression
in AD, the development of AD-like phenotypes in Trim32 KO
mice provides in vivo evidence that defects in innate im-
munity contribute to Th2 polarization and AD pathogenesis.
IMQ is a potent inducer for Th1/Th17 activation and
commonly used to induce psoriasis-like phenotypes in mice
(van der Fits et al., 2009). The development of AD-like phe-
notypes and enhanced Th2 activity in response to IMQ suggest
that Trim32 contributes to the determination of Th cell
response. Pathogen-associated molecular pattern-mediated
innate immunity is essential for the polarization of Th1 and
Th17 to combat viral and bacterial infection. Th2 polarization
is generally inducedwhen innate immunity is compromised as
demonstrated by the evidence from MyD88-deficient mice
(Schnare et al., 2001; Sun et al., 2005) andvaccinationwithout
TLR agonist (Korsholm et al., 2010). The demonstration that
Trim32 KO mice display compromised Th17 response and
enhanced Th2 response in response to IMQ supports the view
that pathogen-associated molecular pattern-mediated innate
immunity determines the polarization of Th cells.
AD is an inflammatory skin disease with defective innate
immunity (Kuo et al., 2013). Patients with AD are susceptible
to bacterial and viral infection. Despite the highly inflamed
nature and the presence of pathogens in AD skin, antimi-
crobial peptide expression is compromised in AD (Ong et al.,
2002). Furthermore, genetic polymorphisms of genes in
innate signaling pathways have been associated with AD,
such as TLR2/9 and NOD1/2. Although the role of defective
innate immunity in AD is appreciated, its contribution in Th2
activation and AD pathogenesis remains to be defined. The
causal role of defective innate immunity was evaluated to
date only in Tlr2 KO mice (Kuo et al., 2013) and Tlr4 KO
mice (Brandt et al., 2013) showing barrier defects but not Th2activation and the infiltration of eosinophils and mast cells. In
the IMQ mouse model, Trim32 KO mice displayed many AD
features including epidermal thickening, enhanced Th2
cytokine expression, infiltration of Th2, mast cells and eo-
sinophils, reduced filaggrin expression, and increased serum
IgE level. Thus, we provide evidence that Trim32 deficiency
can result in a Th2, AD type of skin disorder in response to
TLR activation.
NF-kB activation is essential for innate immune response
and T-cell activation (Hatada et al., 2000). Consistent with
NF-kB activation by Trim32 overexpression (Albor et al.,
2006), we showed that NF-kB activation is compromised
by Trim32 deficiency (Figure 5). As NF-kB signaling is
essential for Th17 differentiation (Bru¨stle et al., 2012;
Molinero et al., 2012), compromised NF-kB activation may
attribute to reduced Th17 activation in Trim32 KO mice.
Similar to Trim32 KO mice, NF-kB inhibition in transgenic
mice with constitutive active IkBa mounted enhanced
allergic inflammation with increased IL-4 expression and
serum IgE (Aronica et al., 1999). Furthermore, RelB KO mice
developed AD-like phenotypes with increased Th2 cytokine
expression and impaired viral clearance in response to
vaccinia viral infection (Freyschmidt et al., 2007). These lines
of evidence suggest that Trim32-mediated NF-kB activation is
critical in determining Th cell differentiation in response to
innate immune activation. Coupled with the low level of
TRIM32 in AD lesional skin, these results provide awww.jidonline.org 363
Figure 6. Evaluation of TRIM32 levels in skin from AD, psoriasis,
and healthy individuals and induction of Trim32 in mouse skin by
toll-like receptor ligand IMQ. (a) Representative images of indirect
immunofluorescence of Trim32 antibody reactivity at 20 magnification. The
white line defines the boundary between epidermis (top) and dermis. Scale
bar ¼ 50 mm. (b) Quantification of integrated density of epidermal TRIM32
staining (AD lesional [AD-L] n¼ 15; AD nonlesional [AD-NL] n¼ 8; psoriasis
lesional [PS-L] n ¼ 7; psoriasis nonlesional [PS-NL] n ¼ 8; control n ¼ 9).
Fluorescence was quantified using FIJI ImageJ Software. Data were
normalized to control group and displayed as a log scale (**P < 0.0001, an
unpaired Student t test). (c) Western blot analysis of Trim32 expression from
the skin of Trim32 WT and KO mice treated with IMQ for 6 days. Total cell
lysates were extracted from the back skin of IMQ-treated mice. GAPDH was
used as loading control. AD, atopic dermatitis; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; IMQ, imiquimod; KO, knockout; TRIM32,
tripartite motif-containing 32; WT, wild type.
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364pathologic basis for defective innate immunity and Th2
activation in patients with AD.
In summary, our data provide in vivo evidence that genetic
manipulation of Trim32 regulates Th17 versus Th2 immunity
in response to TLR activation, supporting findings that
TRIM32 protein expression is defective in AD lesional skin.
Thus, we provide evidence at the molecular level to support
deficiency in innate immunity as leading to Th2 polarization
and AD pathogenesis. Future examination of the contribution
of Trim32 in other genetically modified mouse models that
recapitulate features of human psoriasis or AD, using a wider
array of stimuli, will be critical in further defining the role of
Trim32 in inflammatory diseases and conditions of compro-
mised innate immunity. Expanding knowledge of TRIM32
regulation in skin response to pathogen promises to have
clinical relevance in diagnosis, prognosis of severity, and
subclassification of patients for clinical trials of novel treat-
ments for human inflammatory diseases such as atopic
dermatitis and psoriasis.MATERIALS AND METHODS
Reagents and antibodies
Reagents were purchased as follows: 5% IMQ cream manufactured
by Perrigo (Yeruham, Israel), calcipotriol (MC903) from Cayman
Chemical (Ann Arbor, MI); sirius red (Direct Red 80) from Sigma-
Aldrich (St. Louis, MO); anti-phospho-RelA (S536), anti-TNFAIP3
(A20), anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
anti-phospho-Stat3 (Y705), and anti-phospho-Stat6 (Y641) from Cell
Signaling (Danvers, MA); anti-filaggrin antibody from Santa Cruz
Biotech (Dallas, TX); anti-keratin 5 antibody from LifeSpanJournal of Investigative Dermatology (2017), Volume 137Biosciences (Seattle, WA); anti-GATA3 and anti-IL23R from Abcam
(Cambridge, MA); anti-CD4 from eBioscience (San Diego, CA); and
NovaUltra Toluidine Blue Stain from Fisher Scientific (Pittsburgh,
PA). Rabbit anti-Trim32 antibody for immunoblotting and chicken
anti-Trim32 antibody for immunostaining were generated in our
laboratory (Albor et al., 2006).
Mouse skin inflammation models
Psoriasis-like disease was induced by IMQ in mice as described
previously (van der Fits et al., 2009). Specifically, the back hair of
WT and KO mice was removed using an electric razor. Mice
received a daily topical dose of 62.5 mg IMQ per mouse or Cetaphil
cream vehicle alone as control. Mice deficient in Trim32 and their
WT littermates (provided by Dr. Hao Ding, University of Manitoba,
Canada) were mated into pure FVB genetic background and mixed
background (129XC57BL/6J) and used for the IMQ experiments. FVB
mice were used for MC903 studies as described previously (Zhang
et al., 2009). All animals were bred under specific pathogen-free
conditions and used for experiments at 8e11 weeks of age. Ani-
mals were sex-matched for experiments. All animal experiments
were conducted according to animal protocol (IS00001640)
approved by Oregon Health and Science University.
Mouse primary keratinocyte cell culture and cytokine
treatment
Primary mouse keratinocytes were isolated from the epidermis of
neonatal Trim32 KO and their WT littermates. These cells were
maintained in “low calcium” medium (final concentration of
0.03e0.05 mM Ca2þ) as described (Dlugosz et al., 1995; Kulesz-
Martin et al., 1988). Once the keratinocyte culture reached 100%
confluence, the keratinocytes were treated for 24 hours with species-
specific cytokines: TNF-a (20 ng/ml), IL-4 (50 ng/ml), and IL-17A
(100 ng/ml), purchased from PeproTech (Rocky Hill, NJ).
Human studies
The human subject research component was approved by the Ore-
gon Health and Science University Institutional Review Board
(2568). After informed consent, 4-mm punch biopsies were obtained
from both patients with psoriasis and those with AD and diagnosis
was confirmed after histology was reviewed by a dermatopatholo-
gist. The uninvolved skin biopsies were taken 2e4 cm from the
affected skin. Skin biopsies from healthy individuals with no history
of psoriasis, AD, or inflammatory disease served as controls.
Histologic analysis, mast cell, eosinophil staining, indirect
immunofluorescence, and quantification
Sections (4e6 mm) from mouse back skin were stained with toluidine
blue for mast cells per manufacturer’s instruction (NovaUltra Cat#
IW-3013) or Harris hematoxylin and sirius alkaline red for eosino-
phil (Llewellyn, 1970). Indirect immunofluorescence of TRIM32 in
human tissues and filaggrin in mouse tissues was performed as
described (Liu et al., 2010). For quantification of mast cells and
eosinophils, four pictures of the stained skin sections were taken for
each animal using a 10 objective and 40 objective, respectively,
capturing representation of all the layers of the skin. The number of
mast cells and eosinophils were quantified using ImageJ software
and averaged for each animal.
Quantitative RT-PCR
Total RNAs extracted from back skins or ears in Ambion RNAlater
solution (Fisher Scientific) were converted into total cDNAs using the
RNA-cDNA kit (Applied Biosystems, Foster City, CA). The primers
used are listed in Supplemental Table S1 online.Quantitative PCRwas
Y Liu et al.
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on a real-time PCR system (ViiA 7 Real-Time PCR System).
Immunoblotting analysis, serum IgE and IL-4 detection
Skin tissues were lysed with tissue extraction buffer (100 mM Tris,
pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100,
0.5% sodium deoxycholate) supplemented with both protease in-
hibitor tablet and phosphatase inhibitor tablet (Roche Diagnostics,
Indianapolis, IN). Mouse serum IgE was measured using ELISA kits
from eBioscience, and mouse serum IL-4 was measured using ELISA
kits from Abcam.
Sequential immunohistochemistry
Multiplex sequential immunohistochemistry was performed with
formalin-fixed, paraffin-embedded (5 mm) tissue sections as we
previously reported (Gunderson et al., 2016). Primary rat or rabbit
antibodies were then serially stained for 1 hour at room temperature
using rat anti-CD4 (4SM95, 1:50, eBioscience), Goat anti-IL23R
(1:100, Abcam), and rabbit anti-GATA3 (EPR16651, 1:500,
Abcam). Histofine Simple Stain MAX PO horseradish peroxidase-
conjugated polymer (Nichirei Biosciences) was used for detection
followed by 3-amino-9-ethylcarbazole (AEC) for peroxidase detec-
tion. Multiplex images were coregistered using CellProfiler software
(Broad Institute), deconvoluted using Image J, pseudocolored, and
merged in ImageScope (Aperio, Leica). High magnification images
were created with a 4 zoom from a 20 original magnification.
Total positive cells were manually counted for each cross section,
and the results were normalized to total tissue area.
Statistical analysis
Data values shown are mean  standard deviation. Statistical sig-
nificance was determined by an unpaired Student t test (**) and two-
way analysis of variance followed by the Bonferroni post-test for
multiple comparisons (*) using GraphPad Prism (La Jolla, CA). The P
value is denoted for each analysis and P < 0.05 was considered
statistically significant unless otherwise indicated.
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